FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer
Authors:
- Norihiko SasakiNSNorihiko Sasaki
- Fujiya GomiFGFujiya Gomi
- Hisashi YoshimuraHYHisashi Yoshimura
- Masami YamamotoMYMasami Yamamoto
- Yoko MatsudaYMYoko Matsuda
- Masaki MichishitaMMMasaki Michishita
- Hitoshi HatakeyamaHHHitoshi Hatakeyama
- Yoichi KawanoYKYoichi Kawano
- Masashi ToyodaMTMasashi Toyoda
- Murray KorcMKMurray Korc
- Toshiyuki IshiwataToshiyuki Ishiwata
Open Access
Abstract
Fibroblast growth factor receptor 4 (FGFR4), one of four tyrosine kinase receptors for FGFs, is involved in diverse cellular processes. Activation of FGF19/FGFR4 signaling is closely associated with cancer development and progression. In this study, we examined the expression and roles of FGF19/FGFR4 signaling in human pancreatic ductal adenocarcinoma (PDAC). In human PDAC cases, FGFR4 expression positively correlated with larger primary tumors and more advanced stages. Among eight PDAC cell lines, FGFR4 was expressed at the highest levels in PK-1 cells, in which single-nucleotide polymorphism G388R in FGFR4 was detected. For inhibition of autocrine/paracrine FGF19/FGFR4 signaling, we used BLU9931, a highly selective FGFR4 inhibitor. Inhibition of signal transduction through ERK, AKT, and STAT3 pathways by BLU9931 reduced proliferation in FGF19/FGFR4 signaling-activated PDAC cells. By contrast, BLU9931 did not alter stemness features, including stemness marker expression, anticancer drug resistance, and sphere-forming ability. However, BLU9931 inhibited cell invasion, in part, by downregulating membrane-type matrix metalloproteinase-1 in FGF19/FGFR4 signaling-activated PDAC cells. Furthermore, downregulation of SIRT1 and SIRT6 by BLU9931 contributed to senescence induction, priming these cells for quercetin-induced death, a process termed senolysis. Thus, we propose that BLU9931 is a promising therapeutic agent in FGFR4-positive PDAC, especially when combined with senolysis (195/200).Keywords
Funding Information
- Japan Society for the Promotion of Science (16K10613, 16K08263, 16K10442, 19K11759, 19K09207)
- Pancreas Research Foundation of Japan (To Norihiko Sasaki)
- Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care (To Norihiko Sasaki)
- National Institutes of Health (RO1-075059)
This publication has 93 references indexed in Scilit:
- FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal CancerPLOS ONE, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and OropharynxPLOS ONE, 2012
- Enhanced Expression of Fibroblast Growth Factor Receptor 2 IIIc Promotes Human Pancreatic Cancer Cell ProliferationThe American Journal of Pathology, 2012
- Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLBPLOS ONE, 2012
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic ScreeningCancer Cell, 2011
- FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controlsBMC Cancer, 2011
- Four faces of cellular senescenceJournal of Cell Biology, 2011
- Assessing the significance of chromosomal aberrations in cancer: Methodology and application to gliomaProceedings of the National Academy of Sciences, 2007